New Dual-Target CAR t therapy takes on Hard-to-Treat myeloma
Disease control
Recruiting now
This early-phase study tests a new treatment called O&D-001 for people with multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR T cells) that target two proteins on myeloma cells: BCMA and GPRC5…
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated May 15, 2026 11:55 UTC